The goal of this study is to learn about the safety and effectiveness of intranasal midazolam in newborns and infants born prematurely, undergoing Retinopathy of Prematurity (ROP) screening.
The main question it aims to answer is:
• Does use of intranasal midazolam is a safe, quick, non-invasive medication, that reduces the pain, stress, discomfort, and other complications in patients undergoing ROP screening?
Researchers will compare the intervention group with a comparison group of the patients who will receive routine comfort care.
Obtaining informed consent from a parent/legal guardian.
Newborns/infants not qualified for screening ophthalmologic examination (ROP).
Newborns/infants clinically unstable, with respiratory disorders/cardiovascular instability before the ophthalmologic examination.
Newborns/infants with congenital developmental defects.
Newborns/infants receiving analgesic/sedative medications for other reasons.